Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab plus trastuzumab with neoadjuvant anthracycline-based chemotherapy in HER2-positive breast cancer
2014-000156-28Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of pertuzumab and trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Incidence of left ventricular systolic dysfunction. Started Apr 2014; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-000156-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000156-28.